Clinical study observes frequent mild early filtration decline but rare severe kidney injury in metastatic breast cancer, suggesting long-term renal safety during CDK 4/6 inhibitor therapy.
Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline was common in patients treated with CDK 4/6 inhibitors; however, severe kidney injury is rare and long-term eGFR decline is uncommon.
No takes yet. Share an insight, caveat, or question.
Hanna et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: